In the last 12 months, insiders at JOHNSON & JOHNSON ($JNJ) filed 767 transactions with the SEC: 3 open-market purchases totaling $419,461 and 38 sales totaling $146,741,745. Net insider sentiment: net selling.
JOHNSON & JOHNSON operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Duato Joaquin (CEO and Chairman of the Board) — 66 transactions totaling $157,429,801
- Gorsky Alex (Director) — 3 transactions totaling $103,310,823
- Wolk Joseph J (Exec VP, CFO) — 70 transactions totaling $47,345,578
- REED JOHN C (EVP, Innovative Medicine, R&D) — 35 transactions totaling $37,132,939
- Taubert Jennifer L (EVP, WWC. Innovative Medicine) — 45 transactions totaling $36,583,800
View all SEC Filings for JOHNSON & JOHNSON (JNJ).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 10, 2026 | Woods Eugene A. | Director | A | Deferred Share Units | 155 | $242.14 | 5,240.0940 | 2,429,400,000 | 3.05% | 0.00% |
| March 4, 2025 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 75 | $166.10 | 14,306.4487 | 2,429,400,000 | 0.53% | 0.00% |
| March 10, 2026 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 206 | $242.14 | 14,512.9400 | 2,429,400,000 | 1.44% | 0.00% |
| March 10, 2026 | Pinto Daniel E | Director | A | Deferred Share Units | 129 | $242.14 | 462.0690 | 2,429,400,000 | 38.75% | 0.00% |
| Feb. 27, 2026 | Decker Robert J | VP Corporate Controller | M | Common Stock | 4075 | $115.67 | 28,537.0000 | 2,429,400,000 | 16.66% | 0.00% |
| Feb. 27, 2026 | Decker Robert J | VP Corporate Controller | S | Common Stock | 4075 | $247.87 | 24,462.0000 | 2,429,400,000 | 14.28% | 0.00% |
| Feb. 27, 2026 | Decker Robert J | VP Corporate Controller | M | Employee Stock Options (Right to Buy) | 4075 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | S | Common Stock | 1322 | $245.66 | 26,238.0000 | 2,429,400,000 | 4.80% | 0.00% |
| Feb. 13, 2026 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 1779 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Wolk Joseph J | Exec VP, CFO | M | Performance Share Units | 37463 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | S | Common Stock | 24961 | $242.68 | 85,008.0000 | 2,429,400,000 | 22.70% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | S | Common Stock | 33386 | $242.75 | 109,969.0000 | 2,429,400,000 | 23.29% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 33386 | $131.94 | 143,355.0000 | 2,429,400,000 | 30.36% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | S | Common Stock | 12066 | $242.87 | 109,969.0000 | 2,429,400,000 | 9.89% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 12066 | $129.51 | 122,035.0000 | 2,429,400,000 | 10.97% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | S | Common Stock | 19241 | $242.99 | 109,969.0000 | 2,429,400,000 | 14.89% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 19241 | $115.67 | 129,210.0000 | 2,429,400,000 | 17.50% | 0.00% |
| Feb. 15, 2026 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 817 | $243.45 | 109,969.0000 | 2,429,400,000 | 0.74% | 0.00% |
| Feb. 15, 2026 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 1878 | $0.00 | 110,786.0000 | 2,429,400,000 | 1.72% | 0.00% |
| Feb. 15, 2026 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 858 | $243.45 | 108,908.0000 | 2,429,400,000 | 0.78% | 0.00% |
| Feb. 15, 2026 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 1971 | $0.00 | 109,766.0000 | 2,429,400,000 | 1.83% | 0.00% |
| Feb. 13, 2026 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 507 | $244.55 | 107,795.0000 | 2,429,400,000 | 0.47% | 0.00% |
| Feb. 13, 2026 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 1779 | $0.00 | 108,302.0000 | 2,429,400,000 | 1.67% | 0.00% |
| Feb. 13, 2026 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 15948 | $244.55 | 106,523.0000 | 2,429,400,000 | 13.02% | 0.00% |
| Feb. 13, 2026 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 37463 | $0.00 | 122,471.0000 | 2,429,400,000 | 44.07% | 0.00% |
| Feb. 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | A | Restricted Share Units | 1459 | $0.00 | 1,459.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | A | Employee Stock Options (Right to Buy) | 20322 | $0.00 | 20,322.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Restricted Share Units | 575 | $0.00 | 1,150.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Restricted Share Units | 419 | $0.00 | 418.0000 | 2,429,400,000 | 50.06% | 0.00% |
| Feb. 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Performance Share Units | 3602 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Restricted Share Units | 410 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 251 | $243.45 | 19,830.0000 | 2,429,400,000 | 1.25% | 0.00% |
| Feb. 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 575 | $0.00 | 20,081.0000 | 2,429,400,000 | 2.95% | 0.00% |
| Feb. 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 172 | $243.45 | 19,506.0000 | 2,429,400,000 | 0.87% | 0.00% |
| Feb. 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 419 | $0.00 | 19,678.0000 | 2,429,400,000 | 2.18% | 0.00% |
| Feb. 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 1027 | $244.55 | 19,259.0000 | 2,429,400,000 | 5.06% | 0.00% |
| Feb. 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 3602 | $0.00 | 20,286.0000 | 2,429,400,000 | 21.59% | 0.00% |
| Feb. 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 135 | $244.55 | 16,684.0000 | 2,429,400,000 | 0.80% | 0.00% |
| Feb. 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 410 | $0.00 | 16,819.0000 | 2,429,400,000 | 2.50% | 0.00% |
| Feb. 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Restricted Share Units | 1217 | $0.00 | 1,217.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Employee Stock Options (Right to Buy) | 16945 | $0.00 | 16,945.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 635 | $0.00 | 1,268.0000 | 2,429,400,000 | 33.37% | 0.00% |
| Feb. 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 606 | $0.00 | 606.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 13, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Performance Share Units | 13706 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 651 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 325 | $243.45 | 114,654.8735 | 2,429,400,000 | 0.28% | 0.00% |
| Feb. 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 635 | $0.00 | 114,979.8735 | 2,429,400,000 | 0.56% | 0.00% |
| Feb. 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 310 | $243.45 | 114,344.8735 | 2,429,400,000 | 0.27% | 0.00% |
| Feb. 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 606 | $0.00 | 114,654.8735 | 2,429,400,000 | 0.53% | 0.00% |
| Feb. 13, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 6414 | $244.55 | 114,048.8735 | 2,429,400,000 | 5.32% | 0.00% |
| Feb. 13, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 13706 | $0.00 | 120,462.8735 | 2,429,400,000 | 12.84% | 0.00% |
| Feb. 13, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 217 | $244.55 | 106,756.8735 | 2,429,400,000 | 0.20% | 0.00% |
| Feb. 13, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 651 | $0.00 | 106,973.8735 | 2,429,400,000 | 0.61% | 0.00% |
| Feb. 17, 2026 | Swanson James D. | EVP, CIO | M | Employee Stock Options (Right to Buy) | 20521 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Swanson James D. | EVP, CIO | A | Restricted Share Units | 1397 | $0.00 | 1,397.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Swanson James D. | EVP, CIO | A | Employee Stock Options (Right to Buy) | 19449 | $0.00 | 19,449.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Swanson James D. | EVP, CIO | M | Restricted Share Units | 709 | $0.00 | 1,418.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 15, 2026 | Swanson James D. | EVP, CIO | M | Restricted Share Units | 492 | $0.00 | 491.0000 | 2,429,400,000 | 50.05% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | M | Employee Stock Options (Right to Buy) | 22191 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | M | Employee Stock Options (Right to Buy) | 19368 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | M | Performance Share Units | 9412 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | M | Restricted Share Units | 447 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 17, 2026 | Swanson James D. | EVP, CIO | S | Common Stock | 20521 | $242.70 | 25,698.1310 | 2,429,400,000 | 44.40% | 0.00% |
| Feb. 17, 2026 | Swanson James D. | EVP, CIO | M | Common Stock | 20521 | $164.62 | 46,219.1310 | 2,429,400,000 | 79.85% | 0.00% |
| Feb. 15, 2026 | Swanson James D. | EVP, CIO | F | Common Stock | 309 | $243.45 | 25,698.1310 | 2,429,400,000 | 1.19% | 0.00% |
| Feb. 15, 2026 | Swanson James D. | EVP, CIO | M | Common Stock | 709 | $0.00 | 26,007.1310 | 2,429,400,000 | 2.80% | 0.00% |
| Feb. 15, 2026 | Swanson James D. | EVP, CIO | F | Common Stock | 214 | $243.45 | 25,298.1310 | 2,429,400,000 | 0.84% | 0.00% |
| Feb. 15, 2026 | Swanson James D. | EVP, CIO | M | Common Stock | 492 | $0.00 | 25,512.1310 | 2,429,400,000 | 1.97% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | S | Common Stock | 22191 | $243.71 | 25,020.1310 | 2,429,400,000 | 47.00% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | M | Common Stock | 22191 | $162.75 | 47,211.1310 | 2,429,400,000 | 88.69% | 0.00% |
| Feb. 13, 2026 | Decker Robert J | VP Corporate Controller | F | Common Stock | 104 | $244.55 | 21,985.0000 | 2,429,400,000 | 0.47% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | M | Common Stock | 19368 | $165.89 | 44,388.1310 | 2,429,400,000 | 77.41% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | F | Common Stock | 3547 | $244.55 | 25,020.1310 | 2,429,400,000 | 12.42% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | M | Common Stock | 9412 | $0.00 | 28,567.1310 | 2,429,400,000 | 49.14% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | F | Common Stock | 143 | $244.55 | 19,155.1310 | 2,429,400,000 | 0.74% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | M | Common Stock | 447 | $0.00 | 19,298.1310 | 2,429,400,000 | 2.37% | 0.00% |
| Feb. 15, 2026 | Wolk Joseph J | Exec VP, CFO | A | Restricted Share Units | 3863 | $0.00 | 3,863.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 13, 2026 | Swanson James D. | EVP, CIO | S | Common Stock | 19368 | $243.76 | 25,020.1310 | 2,429,400,000 | 43.63% | 0.00% |
| Feb. 13, 2026 | Decker Robert J | VP Corporate Controller | M | Common Stock | 312 | $0.00 | 22,089.0000 | 2,429,400,000 | 1.43% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | M | Employee Stock Options (Right to Buy) | 33386 | $0.00 | 33,000.0000 | 2,429,400,000 | 50.29% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | M | Employee Stock Options (Right to Buy) | 12066 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 17, 2026 | Wolk Joseph J | Exec VP, CFO | M | Employee Stock Options (Right to Buy) | 19241 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Wolk Joseph J | Exec VP, CFO | A | Employee Stock Options (Right to Buy) | 53793 | $0.00 | 53,793.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 1878 | $0.00 | 3,754.0000 | 2,429,400,000 | 33.35% | 0.00% |
| Feb. 15, 2026 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 1971 | $0.00 | 1,971.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 15, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 270 | $243.45 | 29,200.0000 | 2,429,400,000 | 0.92% | 0.00% |
| Feb. 15, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 526 | $0.00 | 29,470.0000 | 2,429,400,000 | 1.82% | 0.00% |
| Feb. 15, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 252 | $243.45 | 28,944.0000 | 2,429,400,000 | 0.86% | 0.00% |
| Feb. 15, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 492 | $0.00 | 29,196.0000 | 2,429,400,000 | 1.71% | 0.00% |
| Feb. 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 3748 | $244.55 | 28,704.0000 | 2,429,400,000 | 11.55% | 0.00% |
| Feb. 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 8594 | $0.00 | 32,452.0000 | 2,429,400,000 | 36.02% | 0.00% |
| Feb. 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 144 | $244.55 | 23,858.0000 | 2,429,400,000 | 0.60% | 0.00% |
| Feb. 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 408 | $0.00 | 24,002.0000 | 2,429,400,000 | 1.73% | 0.00% |
| Feb. 15, 2026 | Duato Joaquin | CEO and Chairman of the Board | A | Restricted Share Units | 9459 | $0.00 | 9,459.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Duato Joaquin | CEO and Chairman of the Board | A | Employee Stock Options (Right to Buy) | 131734 | $0.00 | 131,734.0000 | 2,429,400,000 | 9999.99% | 0.01% |
| Feb. 15, 2026 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 4505 | $0.00 | 9,008.0000 | 2,429,400,000 | 33.34% | 0.00% |
| Feb. 15, 2026 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 3682 | $0.00 | 3,682.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | M | Performance Share Units | 73054 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 3469 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 1960 | $243.45 | 356,297.0000 | 2,429,400,000 | 0.55% | 0.00% |
| Feb. 15, 2026 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 4505 | $0.00 | 358,257.0000 | 2,429,400,000 | 1.27% | 0.00% |
| Feb. 15, 2026 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 1602 | $243.45 | 353,752.0000 | 2,429,400,000 | 0.45% | 0.00% |
| Feb. 15, 2026 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 3682 | $0.00 | 355,354.0000 | 2,429,400,000 | 1.05% | 0.00% |
| Feb. 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 31679 | $244.55 | 351,672.0000 | 2,429,400,000 | 8.26% | 0.00% |
| Feb. 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 73054 | $0.00 | 383,351.0000 | 2,429,400,000 | 23.54% | 0.00% |
| Feb. 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 989 | $244.55 | 310,297.0000 | 2,429,400,000 | 0.32% | 0.00% |
| Feb. 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 3469 | $0.00 | 311,286.0000 | 2,429,400,000 | 1.13% | 0.00% |
| Feb. 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Employee Stock Options (Right to Buy) | 8998 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Employee Stock Options (Right to Buy) | 13625 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | A | Restricted Share Units | 2548 | $0.00 | 2,548.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | A | Employee Stock Options (Right to Buy) | 35489 | $0.00 | 35,489.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Restricted Share Units | 1026 | $0.00 | 2,051.0000 | 2,429,400,000 | 33.34% | 0.00% |
| Feb. 15, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Restricted Share Units | 1028 | $0.00 | 1,028.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Performance Share Units | 4378 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Restricted Share Units | 499 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | S | Common Stock | 8998 | $244.53 | 27,560.0000 | 2,429,400,000 | 24.61% | 0.00% |
| Feb. 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 8998 | $129.51 | 36,558.0000 | 2,429,400,000 | 32.65% | 0.00% |
| Feb. 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | S | Common Stock | 13625 | $244.20 | 27,560.0000 | 2,429,400,000 | 33.08% | 0.00% |
| Feb. 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 13625 | $115.67 | 41,185.0000 | 2,429,400,000 | 49.44% | 0.00% |
| Feb. 15, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 448 | $243.45 | 27,560.0000 | 2,429,400,000 | 1.60% | 0.00% |
| Feb. 15, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 1026 | $0.00 | 28,008.0000 | 2,429,400,000 | 3.80% | 0.00% |
| Feb. 15, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 15 | $243.45 | 26,982.0000 | 2,429,400,000 | 0.06% | 0.00% |
| Feb. 15, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 1028 | $0.00 | 26,997.0000 | 2,429,400,000 | 3.96% | 0.00% |
| Feb. 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 1816 | $244.55 | 25,969.0000 | 2,429,400,000 | 6.54% | 0.00% |
| Feb. 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 4378 | $0.00 | 27,785.0000 | 2,429,400,000 | 18.70% | 0.00% |
| Feb. 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 8 | $244.55 | 23,407.0000 | 2,429,400,000 | 0.03% | 0.00% |
| Feb. 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 499 | $0.00 | 23,415.0000 | 2,429,400,000 | 2.18% | 0.00% |
| Feb. 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | Restricted Share Units | 3940 | $0.00 | 3,940.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | Employee Stock Options (Right to Buy) | 54869 | $0.00 | 54,869.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Restricted Share Units | 1847 | $0.00 | 3,692.0000 | 2,429,400,000 | 33.35% | 0.00% |
| Feb. 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Restricted Share Units | 1594 | $0.00 | 1,594.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Performance Share Units | 27412 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Restricted Share Units | 1302 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 945 | $243.45 | 194,451.0010 | 2,429,400,000 | 0.48% | 0.00% |
| Feb. 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 1847 | $0.00 | 195,396.0010 | 2,429,400,000 | 0.95% | 0.00% |
| Feb. 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 816 | $243.45 | 193,549.0010 | 2,429,400,000 | 0.42% | 0.00% |
| Feb. 15, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 1594 | $0.00 | 194,365.0010 | 2,429,400,000 | 0.83% | 0.00% |
| Feb. 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 13547 | $244.55 | 192,771.0010 | 2,429,400,000 | 6.57% | 0.00% |
| Feb. 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 27412 | $0.00 | 206,318.0010 | 2,429,400,000 | 15.32% | 0.00% |
| Feb. 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 409 | $244.55 | 178,906.0010 | 2,429,400,000 | 0.23% | 0.00% |
| Feb. 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 1302 | $0.00 | 179,315.0010 | 2,429,400,000 | 0.73% | 0.00% |
| Feb. 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | A | Restricted Share Units | 1944 | $0.00 | 1,944.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | A | Employee Stock Options (Right to Buy) | 27076 | $0.00 | 27,076.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Restricted Share Units | 1063 | $0.00 | 2,126.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Restricted Share Units | 961 | $0.00 | 961.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Performance Share Units | 13706 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Restricted Share Units | 651 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | F | Common Stock | 544 | $243.45 | 23,568.0000 | 2,429,400,000 | 2.26% | 0.00% |
| Feb. 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Common Stock | 1063 | $0.00 | 24,112.0000 | 2,429,400,000 | 4.61% | 0.00% |
| Feb. 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | F | Common Stock | 492 | $243.45 | 23,049.0000 | 2,429,400,000 | 2.09% | 0.00% |
| Feb. 15, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Common Stock | 961 | $0.00 | 23,541.0000 | 2,429,400,000 | 4.26% | 0.00% |
| Feb. 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | F | Common Stock | 7011 | $244.55 | 22,580.0000 | 2,429,400,000 | 23.69% | 0.00% |
| Feb. 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Common Stock | 13706 | $0.00 | 29,591.0000 | 2,429,400,000 | 86.28% | 0.00% |
| Feb. 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | F | Common Stock | 314 | $244.55 | 15,885.0000 | 2,429,400,000 | 1.94% | 0.00% |
| Feb. 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Common Stock | 651 | $0.00 | 16,199.0000 | 2,429,400,000 | 4.19% | 0.00% |
| Feb. 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Employee Stock Options (Right to Buy) | 29927 | $0.00 | 59,854.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Employee Stock Options (Right to Buy) | 21721 | $0.00 | 21,721.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | A | Restricted Share Units | 3546 | $0.00 | 3,546.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | A | Employee Stock Options (Right to Buy) | 49382 | $0.00 | 49,382.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 1847 | $0.00 | 3,692.0000 | 2,429,400,000 | 33.35% | 0.00% |
| Feb. 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 1349 | $0.00 | 1,349.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 2283 | $243.00 | 10,658.0000 | 2,429,400,000 | 17.64% | 0.00% |
| Feb. 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 29927 | $243.00 | 12,941.0000 | 2,429,400,000 | 69.81% | 0.00% |
| Feb. 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 29927 | $156.15 | 42,868.0000 | 2,429,400,000 | 231.26% | 0.00% |
| Feb. 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 21721 | $243.00 | 12,941.0000 | 2,429,400,000 | 62.67% | 0.00% |
| Feb. 17, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 21721 | $157.92 | 34,662.0000 | 2,429,400,000 | 167.85% | 0.00% |
| Feb. 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 528 | $243.45 | 12,941.0000 | 2,429,400,000 | 3.92% | 0.00% |
| Feb. 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 1847 | $0.00 | 13,469.0000 | 2,429,400,000 | 15.89% | 0.00% |
| Feb. 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 385 | $243.45 | 11,622.0000 | 2,429,400,000 | 3.21% | 0.00% |
| Feb. 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 1349 | $0.00 | 12,007.0000 | 2,429,400,000 | 12.66% | 0.00% |
| Feb. 15, 2026 | Decker Robert J | VP Corporate Controller | A | Restricted Share Units | 700 | $0.00 | 700.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Decker Robert J | VP Corporate Controller | A | Employee Stock Options (Right to Buy) | 4871 | $0.00 | 4,871.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 344 | $0.00 | 687.0000 | 2,429,400,000 | 33.37% | 0.00% |
| Feb. 15, 2026 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 339 | $0.00 | 338.0000 | 2,429,400,000 | 50.07% | 0.00% |
| Feb. 13, 2026 | Decker Robert J | VP Corporate Controller | M | Performance Share Units | 2741 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 312 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2026 | Decker Robert J | VP Corporate Controller | F | Common Stock | 95 | $243.45 | 24,458.0000 | 2,429,400,000 | 0.39% | 0.00% |
| Feb. 15, 2026 | Decker Robert J | VP Corporate Controller | M | Common Stock | 344 | $0.00 | 24,553.0000 | 2,429,400,000 | 1.42% | 0.00% |
| Feb. 15, 2026 | Decker Robert J | VP Corporate Controller | F | Common Stock | 94 | $243.45 | 24,209.0000 | 2,429,400,000 | 0.39% | 0.00% |
| Feb. 15, 2026 | Decker Robert J | VP Corporate Controller | M | Common Stock | 339 | $0.00 | 24,303.0000 | 2,429,400,000 | 1.41% | 0.00% |
| Feb. 13, 2026 | Decker Robert J | VP Corporate Controller | F | Common Stock | 762 | $244.55 | 23,964.0000 | 2,429,400,000 | 3.08% | 0.00% |
| Feb. 13, 2026 | Decker Robert J | VP Corporate Controller | M | Common Stock | 2741 | $0.00 | 24,726.0000 | 2,429,400,000 | 12.47% | 0.00% |
| Feb. 15, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Restricted Share Units | 1034 | $0.00 | 1,034.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Employee Stock Options (Right to Buy) | 14405 | $0.00 | 14,405.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 526 | $0.00 | 1,050.0000 | 2,429,400,000 | 33.38% | 0.00% |
| Feb. 15, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 492 | $0.00 | 491.0000 | 2,429,400,000 | 50.05% | 0.00% |
| Feb. 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Performance Share Units | 8594 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 408 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 17, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | S | Common Stock | 6197 | $243.39 | 23,003.0000 | 2,429,400,000 | 21.22% | 0.00% |
| Feb. 9, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Performance Share Units | 13706 | $0.00 | 13,706.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Performance Share Units | 8594 | $0.00 | 8,594.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Wolk Joseph J | Exec VP, CFO | A | Performance Share Units | 37463 | $0.00 | 37,463.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | Performance Share Units | 27412 | $0.00 | 27,412.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Swanson James D. | EVP, CIO | A | Performance Share Units | 9412 | $0.00 | 9,412.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | A | Performance Share Units | 4378 | $0.00 | 4,378.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Mulholland Kristen | EVP, Chief HR Officer | A | Performance Share Units | 3602 | $0.00 | 3,602.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | A | Performance Share Units | 13706 | $0.00 | 13,706.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Duato Joaquin | CEO and Chairman of the Board | A | Performance Share Units | 73054 | $0.00 | 73,054.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 9, 2026 | Decker Robert J | VP Corporate Controller | A | Performance Share Units | 2741 | $0.00 | 2,741.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Employee Stock Options (Right to Buy) | 15571 | $101.87 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 15571 | $101.87 | 33,251.0000 | 2,429,400,000 | 88.07% | 0.00% |
| Feb. 6, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 10335 | $239.99 | 22,916.0000 | 2,429,400,000 | 31.08% | 0.00% |
| Feb. 6, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 5625 | $101.87 | 19,744.0000 | 2,429,400,000 | 39.84% | 0.00% |
| Feb. 6, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Employee Stock Options (Right to Buy) | 38945 | $101.87 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 6, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 27270 | $239.99 | 106,322.8735 | 2,429,400,000 | 20.41% | 0.00% |
| Feb. 6, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 38945 | $101.87 | 133,592.8735 | 2,429,400,000 | 41.15% | 0.00% |
| Feb. 6, 2026 | Mulholland Kristen | EVP, Chief HR Officer | M | Employee Stock Options (Right to Buy) | 5625 | $101.87 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 6, 2026 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 3335 | $239.99 | 16,409.0000 | 2,429,400,000 | 16.89% | 0.00% |
| Feb. 5, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Common Stock | 8921 | $129.51 | 21,774.0000 | 2,429,400,000 | 69.41% | 0.00% |
| Feb. 5, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | M | Employee Stock Options (Right to Buy) | 8921 | $129.51 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 5, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | F | Common Stock | 6226 | $237.90 | 15,548.0000 | 2,429,400,000 | 28.59% | 0.00% |
| Jan. 26, 2026 | Duato Joaquin | CEO and Chairman of the Board | S | Common Stock | 51218 | $220.99 | 356,589.0000 | 2,429,400,000 | 12.56% | 0.00% |
| Jan. 26, 2026 | Duato Joaquin | CEO and Chairman of the Board | S | Common Stock | 48782 | $221.48 | 307,807.0000 | 2,429,400,000 | 13.68% | 0.00% |
| Aug. 23, 2023 | Johnson Paula A | Director | D | Common Stock | 11 | $0.00 | 89.0000 | 2,663,900,000 | 11.00% | 0.00% |
| Nov. 25, 2025 | JOHNSON & JOHNSON | Not found | S | Common Stock | 16000 | $10.03 | 4,031,198.0000 | 2,428,600,000 | 0.40% | 0.00% |
| Nov. 26, 2025 | JOHNSON & JOHNSON | Not found | S | Common Stock | 6337 | $10.03 | 4,024,861.0000 | 2,428,600,000 | 0.16% | 0.00% |
| Dec. 9, 2025 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 247 | $202.12 | 14,153.1187 | 2,428,600,000 | 1.78% | 0.00% |
| Dec. 9, 2025 | Pinto Daniel E | Director | A | Deferred Share Units | 155 | $202.12 | 331.2330 | 2,428,600,000 | 87.54% | 0.00% |
| Dec. 9, 2025 | Woods Eugene A. | Director | A | Deferred Share Units | 186 | $202.12 | 5,058.0682 | 2,428,600,000 | 3.81% | 0.00% |
| Nov. 26, 2025 | JOHNSON & JOHNSON | Not found | S | Common Stock | 6337 | $10.03 | 4,040,861.0000 | 2,428,600,000 | 0.16% | 0.00% |
| Nov. 26, 2025 | MORIKIS JOHN G | Director | P | Common Stock | 1250 | $206.15 | 1,848.5100 | 2,428,600,000 | 208.85% | 0.00% |
| Nov. 24, 2025 | JOHNSON & JOHNSON | Not found | S | Common Stock | 2200 | $10.06 | 4,047,198.0000 | 2,428,600,000 | 0.05% | 0.00% |
| Nov. 21, 2025 | JOHNSON & JOHNSON | Not found | S | Common Stock | 500 | $10.00 | 4,049,398.0000 | 2,428,600,000 | 0.01% | 0.00% |
| Oct. 17, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Employee Stock Options (Right to Buy) | 21721 | $157.92 | 43,442.0000 | 2,428,600,000 | 33.33% | 0.00% |
| Oct. 17, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 21721 | $192.71 | 10,658.0000 | 2,428,600,000 | 67.08% | 0.00% |
| Oct. 17, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 21721 | $157.92 | 32,379.0000 | 2,428,600,000 | 203.80% | 0.00% |
| Sept. 9, 2025 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 281 | $178.07 | 13,816.8727 | 2,429,400,000 | 2.07% | 0.00% |
| Sept. 9, 2025 | Pinto Daniel E | Director | A | Deferred Share Units | 175 | $178.07 | 175.4930 | 2,429,400,000 | 9999.99% | 0.00% |
| Sept. 9, 2025 | Woods Eugene A. | Director | A | Deferred Share Units | 211 | $178.07 | 4,841.3962 | 2,429,400,000 | 4.55% | 0.00% |
| Sept. 4, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Employee Stock Options (Right to Buy) | 56471 | $101.87 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Sept. 4, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 56471 | $101.87 | 234,484.0010 | 2,429,400,000 | 31.72% | 0.00% |
| Sept. 4, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S | Common Stock | 56471 | $177.81 | 178,013.0010 | 2,429,400,000 | 24.08% | 0.00% |
| Aug. 29, 2025 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 9570 | $177.20 | 12,853.0000 | 2,429,400,000 | 42.68% | 0.00% |
| Aug. 29, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Employee Stock Options (Right to Buy) | 11521 | $115.67 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Aug. 29, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 11521 | $115.67 | 22,423.0000 | 2,429,400,000 | 105.68% | 0.00% |
| Aug. 22, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Employee Stock Options (Right to Buy) | 125824 | $101.87 | 0.0000 | 2,429,400,000 | 100.00% | 0.01% |
| Aug. 22, 2025 | Duato Joaquin | CEO and Chairman of the Board | S | Common Stock | 125824 | $179.21 | 407,793.0000 | 2,429,400,000 | 23.58% | 0.01% |
| Aug. 22, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 125824 | $101.87 | 533,617.0000 | 2,429,400,000 | 30.85% | 0.01% |
| Aug. 15, 2025 | Wolk Joseph J | Exec VP, CFO | M | Employee Stock Options (Right to Buy) | 16820 | $101.87 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Aug. 15, 2025 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 16820 | $101.87 | 101,800.0000 | 2,429,400,000 | 19.79% | 0.00% |
| Aug. 15, 2025 | Wolk Joseph J | Exec VP, CFO | S | Common Stock | 16820 | $176.91 | 84,980.0000 | 2,429,400,000 | 16.52% | 0.00% |
| July 17, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | S | Common Stock | 19137 | $163.55 | 10,658.0000 | 2,429,400,000 | 64.23% | 0.00% |
| June 10, 2025 | Woods Eugene A. | Director | A | Deferred Share Units | 231 | $155.23 | 4,597.2422 | 2,429,400,000 | 5.30% | 0.00% |
| June 10, 2025 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 322 | $155.23 | 13,437.9807 | 2,429,400,000 | 2.46% | 0.00% |
| May 1, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 25255 | $0.00 | 25,255.0000 | 2,429,400,000 | 50.00% | 0.00% |
| May 1, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 11002 | $156.31 | 29,795.0000 | 2,429,400,000 | 26.97% | 0.00% |
| May 1, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 25255 | $0.00 | 40,797.0000 | 2,429,400,000 | 162.50% | 0.00% |
| April 24, 2025 | Beckerle Mary C | Director | A | Deferred Share Units | 1316 | $0.00 | 15,395.3983 | 2,429,400,000 | 9.35% | 0.00% |
| April 24, 2025 | Woods Eugene A. | Director | A | Deferred Share Units | 1316 | $0.00 | 4,329.6642 | 2,429,400,000 | 43.67% | 0.00% |
| April 24, 2025 | West Nadja | Director | A | Deferred Share Units | 1316 | $0.00 | 6,572.6091 | 2,429,400,000 | 25.04% | 0.00% |
| April 24, 2025 | WEINBERGER MARK A | Director | A | Deferred Share Units | 1316 | $0.00 | 10,737.3640 | 2,429,400,000 | 13.97% | 0.00% |
| April 24, 2025 | McClellan Mark B. | Director | A | Deferred Share Units | 1316 | $0.00 | 19,755.2320 | 2,429,400,000 | 7.14% | 0.00% |
| April 24, 2025 | Joly Hubert | Director | A | Deferred Share Units | 1316 | $0.00 | 7,986.9070 | 2,429,400,000 | 19.73% | 0.00% |
| April 24, 2025 | Johnson Paula A | Director | A | Deferred Share Units | 1316 | $0.00 | 4,265.9823 | 2,429,400,000 | 44.61% | 0.00% |
| April 24, 2025 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 1316 | $0.00 | 13,006.9497 | 2,429,400,000 | 11.26% | 0.00% |
| April 24, 2025 | Doudna Jennifer A | Director | A | Deferred Share Units | 1316 | $0.00 | 9,656.1384 | 2,429,400,000 | 15.78% | 0.00% |
| March 18, 2025 | Duato Joaquin | CEO and Chairman of the Board | G | Common Stock | 130852 | $0.00 | 407,782.0000 | 2,429,400,000 | 47.25% | 0.01% |
| March 18, 2025 | Duato Joaquin | CEO and Chairman of the Board | G | Common Stock | 130852 | $0.00 | 407,782.0000 | 2,429,400,000 | 24.29% | 0.01% |
| March 4, 2025 | Woods Eugene A. | Director | A | Deferred Share Units | 188 | $166.10 | 3,013.6642 | 2,429,400,000 | 6.66% | 0.00% |
| March 4, 2025 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 226 | $166.10 | 11,690.9497 | 2,429,400,000 | 1.97% | 0.00% |
| April 30, 2024 | Woods Eugene A. | Director | P | Common Stock | 100 | $145.53 | 400.0000 | 2,560,400,000 | 33.33% | 0.00% |
| Feb. 25, 2025 | Decker Robert J | VP Corporate Controller | S | Common Stock | 6999 | $165.88 | 21,755.0000 | 2,429,400,000 | 24.34% | 0.00% |
| Feb. 25, 2025 | Decker Robert J | VP Corporate Controller | M | Employee Stock Options (Right to Buy) | 6999 | $101.87 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 25, 2025 | Decker Robert J | VP Corporate Controller | M | Common Stock | 6999 | $101.87 | 28,754.0000 | 2,429,400,000 | 32.17% | 0.00% |
| Feb. 15, 2025 | Forminard Elizabeth | Executive VP, General Counsel | A | Restricted Share Units | 3189 | $0.00 | 3,189.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Decker Robert J | VP Corporate Controller | A | Restricted Share Units | 1031 | $0.00 | 1,031.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Duato Joaquin | CEO and Chairman of the Board | A | Employee Stock Options (Right to Buy) | 219020 | $0.00 | 219,020.0000 | 2,429,400,000 | 9999.99% | 0.01% |
| Feb. 15, 2025 | Duato Joaquin | CEO and Chairman of the Board | A | Restricted Share Units | 13513 | $0.00 | 13,513.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Employee Stock Options (Right to Buy) | 25538 | $0.00 | 25,538.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Restricted Share Units | 1576 | $0.00 | 1,576.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Restricted Share Units | 1903 | $0.00 | 1,903.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Employee Stock Options (Right to Buy) | 30841 | $0.00 | 30,841.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Mulholland Kristen | EVP, Chief HR Officer | A | Restricted Share Units | 1725 | $0.00 | 1,725.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Wolk Joseph J | Exec VP, CFO | A | Employee Stock Options (Right to Buy) | 91277 | $0.00 | 91,277.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Wolk Joseph J | Exec VP, CFO | A | Restricted Share Units | 5632 | $0.00 | 5,632.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Mulholland Kristen | EVP, Chief HR Officer | A | Employee Stock Options (Right to Buy) | 27951 | $0.00 | 27,951.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | A | Restricted Share Units | 5539 | $0.00 | 5,539.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | A | Employee Stock Options (Right to Buy) | 89781 | $0.00 | 89,781.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | A | Restricted Share Units | 3077 | $0.00 | 3,077.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | A | Employee Stock Options (Right to Buy) | 49878 | $0.00 | 49,878.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Swanson James D. | EVP, CIO | A | Restricted Share Units | 2127 | $0.00 | 2,127.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Swanson James D. | EVP, CIO | A | Employee Stock Options (Right to Buy) | 34476 | $0.00 | 34,476.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | Restricted Share Units | 5539 | $0.00 | 5,539.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | Employee Stock Options (Right to Buy) | 89781 | $0.00 | 89,781.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Forminard Elizabeth | Executive VP, General Counsel | A | Employee Stock Options (Right to Buy) | 51688 | $0.00 | 51,688.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2025 | Decker Robert J | VP Corporate Controller | A | Employee Stock Options (Right to Buy) | 8357 | $0.00 | 8,357.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 13, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Restricted Share Units | 1302 | $0.00 | 1,302.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 14, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 2806 | $0.00 | 18,672.0000 | 2,429,400,000 | 17.69% | 0.00% |
| Feb. 14, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 1015 | $156.71 | 17,657.0000 | 2,429,400,000 | 5.44% | 0.00% |
| Feb. 14, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | M | Performance Share Units | 2806 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 499 | $0.00 | 13,539.0000 | 2,429,400,000 | 3.83% | 0.00% |
| Feb. 14, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 193 | $155.26 | 13,346.0000 | 2,429,400,000 | 1.43% | 0.00% |
| Feb. 14, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 1765 | $0.00 | 15,111.0000 | 2,429,400,000 | 13.22% | 0.00% |
| Feb. 14, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 639 | $156.71 | 14,472.0000 | 2,429,400,000 | 4.23% | 0.00% |
| Feb. 15, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 1029 | $0.00 | 15,501.0000 | 2,429,400,000 | 7.11% | 0.00% |
| Feb. 18, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | S | Common Stock | 403 | $156.15 | 15,098.0000 | 2,429,400,000 | 2.60% | 0.00% |
| Feb. 13, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | M | Restricted Share Units | 499 | $0.00 | 499.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 14, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | M | Restricted Share Units | 1765 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | M | Restricted Share Units | 1029 | $0.00 | 2,056.0000 | 2,429,400,000 | 33.35% | 0.00% |
| Feb. 13, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 651 | $0.00 | 89,958.8735 | 2,429,400,000 | 0.73% | 0.00% |
| Feb. 14, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 223 | $155.26 | 89,735.8735 | 2,429,400,000 | 0.25% | 0.00% |
| Feb. 14, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 1530 | $0.00 | 91,265.8735 | 2,429,400,000 | 1.71% | 0.00% |
| Feb. 14, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 480 | $156.71 | 90,785.8735 | 2,429,400,000 | 0.53% | 0.00% |
| Feb. 15, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 607 | $0.00 | 91,392.8735 | 2,429,400,000 | 0.67% | 0.00% |
| Feb. 18, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 200 | $156.15 | 91,192.8735 | 2,429,400,000 | 0.22% | 0.00% |
| Feb. 14, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 5837 | $0.00 | 97,029.8735 | 2,429,400,000 | 6.40% | 0.00% |
| Feb. 14, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 2393 | $156.71 | 94,636.8735 | 2,429,400,000 | 2.47% | 0.00% |
| Feb. 13, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 651 | $0.00 | 651.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 14, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 1530 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 607 | $0.00 | 1,212.0000 | 2,429,400,000 | 33.37% | 0.00% |
| Feb. 14, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Performance Share Units | 5837 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2025 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 1779 | $0.00 | 72,727.0000 | 2,429,400,000 | 2.51% | 0.00% |
| Feb. 14, 2025 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 507 | $155.26 | 72,220.0000 | 2,429,400,000 | 0.70% | 0.00% |
| Feb. 14, 2025 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 4014 | $0.00 | 76,234.0000 | 2,429,400,000 | 5.56% | 0.00% |
| Feb. 14, 2025 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 1144 | $156.71 | 75,090.0000 | 2,429,400,000 | 1.50% | 0.00% |
| Feb. 15, 2025 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 1971 | $0.00 | 77,061.0000 | 2,429,400,000 | 2.62% | 0.00% |
| Feb. 18, 2025 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 768 | $156.15 | 76,293.0000 | 2,429,400,000 | 1.00% | 0.00% |
| Feb. 14, 2025 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 15316 | $0.00 | 91,609.0000 | 2,429,400,000 | 20.08% | 0.00% |
| Feb. 14, 2025 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 6661 | $156.71 | 84,948.0000 | 2,429,400,000 | 7.27% | 0.00% |
| Feb. 13, 2025 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 1779 | $0.00 | 1,779.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 14, 2025 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 4014 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 1971 | $0.00 | 3,942.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 14, 2025 | Wolk Joseph J | Exec VP, CFO | M | Performance Share Units | 15316 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 1350 | $0.00 | 15,927.0000 | 2,429,400,000 | 9.26% | 0.00% |
| Feb. 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 385 | $156.15 | 15,542.0000 | 2,429,400,000 | 2.42% | 0.00% |
| Feb. 15, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 1350 | $0.00 | 2,698.0000 | 2,429,400,000 | 33.35% | 0.00% |
| Feb. 13, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 1302 | $0.00 | 167,221.0010 | 2,429,400,000 | 0.78% | 0.00% |
| Feb. 14, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 410 | $155.26 | 166,811.0010 | 2,429,400,000 | 0.25% | 0.00% |
| Feb. 14, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 4053 | $0.00 | 170,864.0010 | 2,429,400,000 | 2.43% | 0.00% |
| Feb. 14, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 1348 | $156.71 | 169,516.0010 | 2,429,400,000 | 0.79% | 0.00% |
| Feb. 15, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 1594 | $0.00 | 171,110.0010 | 2,429,400,000 | 0.94% | 0.00% |
| Feb. 18, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 651 | $156.15 | 170,459.0010 | 2,429,400,000 | 0.38% | 0.00% |
| Feb. 14, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 15465 | $0.00 | 185,924.0010 | 2,429,400,000 | 9.07% | 0.00% |
| Feb. 14, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 7911 | $156.71 | 178,013.0010 | 2,429,400,000 | 4.25% | 0.00% |
| Feb. 14, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Restricted Share Units | 4053 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Restricted Share Units | 1594 | $0.00 | 3,188.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 14, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Performance Share Units | 15465 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2025 | Swanson James D. | EVP, CIO | M | Common Stock | 447 | $0.00 | 15,018.5900 | 2,429,400,000 | 3.07% | 0.00% |
| Feb. 14, 2025 | Swanson James D. | EVP, CIO | F | Common Stock | 152 | $155.26 | 14,866.5900 | 2,429,400,000 | 1.01% | 0.00% |
| Feb. 14, 2025 | Swanson James D. | EVP, CIO | M | Common Stock | 1961 | $0.00 | 16,827.5900 | 2,429,400,000 | 13.19% | 0.00% |
| Feb. 14, 2025 | Swanson James D. | EVP, CIO | F | Common Stock | 558 | $156.71 | 16,269.5900 | 2,429,400,000 | 3.32% | 0.00% |
| Feb. 15, 2025 | Swanson James D. | EVP, CIO | M | Common Stock | 492 | $0.00 | 16,761.5900 | 2,429,400,000 | 3.02% | 0.00% |
| Feb. 18, 2025 | Swanson James D. | EVP, CIO | F | Common Stock | 141 | $156.15 | 16,620.5900 | 2,429,400,000 | 0.84% | 0.00% |
| Feb. 14, 2025 | Swanson James D. | EVP, CIO | M | Common Stock | 3118 | $0.00 | 19,738.5900 | 2,429,400,000 | 18.76% | 0.00% |
| Feb. 14, 2025 | Swanson James D. | EVP, CIO | F | Common Stock | 889 | $156.71 | 18,849.5900 | 2,429,400,000 | 4.50% | 0.00% |
| Feb. 13, 2025 | Swanson James D. | EVP, CIO | M | Restricted Share Units | 447 | $0.00 | 447.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 14, 2025 | Swanson James D. | EVP, CIO | M | Restricted Share Units | 1961 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Swanson James D. | EVP, CIO | M | Restricted Share Units | 492 | $0.00 | 983.0000 | 2,429,400,000 | 33.36% | 0.00% |
| Feb. 14, 2025 | Swanson James D. | EVP, CIO | M | Performance Share Units | 3118 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2025 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 411 | $0.00 | 12,100.0000 | 2,429,400,000 | 3.52% | 0.00% |
| Feb. 14, 2025 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 141 | $155.26 | 11,959.0000 | 2,429,400,000 | 1.17% | 0.00% |
| Feb. 14, 2025 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 1007 | $0.00 | 12,966.0000 | 2,429,400,000 | 8.42% | 0.00% |
| Feb. 14, 2025 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 290 | $156.71 | 12,676.0000 | 2,429,400,000 | 2.24% | 0.00% |
| Feb. 15, 2025 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 419 | $0.00 | 13,095.0000 | 2,429,400,000 | 3.31% | 0.00% |
| Feb. 18, 2025 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 120 | $156.15 | 12,975.0000 | 2,429,400,000 | 0.92% | 0.00% |
| Feb. 14, 2025 | Mulholland Kristen | EVP, Chief HR Officer | M | Common Stock | 1601 | $0.00 | 14,576.0000 | 2,429,400,000 | 12.34% | 0.00% |
| Feb. 14, 2025 | Mulholland Kristen | EVP, Chief HR Officer | F | Common Stock | 457 | $156.71 | 14,119.0000 | 2,429,400,000 | 3.14% | 0.00% |
| Feb. 13, 2025 | Mulholland Kristen | EVP, Chief HR Officer | M | Restricted Share Units | 411 | $0.00 | 410.0000 | 2,429,400,000 | 50.06% | 0.00% |
| Feb. 14, 2025 | Mulholland Kristen | EVP, Chief HR Officer | M | Restricted Share Units | 1007 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Mulholland Kristen | EVP, Chief HR Officer | M | Restricted Share Units | 419 | $0.00 | 837.0000 | 2,429,400,000 | 33.36% | 0.00% |
| Feb. 14, 2025 | Mulholland Kristen | EVP, Chief HR Officer | M | Performance Share Units | 1601 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 651 | $0.00 | 8,991.0000 | 2,429,400,000 | 7.81% | 0.00% |
| Feb. 14, 2025 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 215 | $155.26 | 8,776.0000 | 2,429,400,000 | 2.39% | 0.00% |
| Feb. 14, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 851 | $0.00 | 9,627.0000 | 2,429,400,000 | 9.70% | 0.00% |
| Feb. 14, 2025 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 267 | $156.71 | 9,360.0000 | 2,429,400,000 | 2.77% | 0.00% |
| Feb. 15, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 961 | $0.00 | 10,321.0000 | 2,429,400,000 | 10.27% | 0.00% |
| Feb. 18, 2025 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 307 | $156.15 | 10,014.0000 | 2,429,400,000 | 2.97% | 0.00% |
| Feb. 14, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 1352 | $0.00 | 11,366.0000 | 2,429,400,000 | 13.50% | 0.00% |
| Feb. 14, 2025 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 464 | $156.71 | 10,902.0000 | 2,429,400,000 | 4.08% | 0.00% |
| Feb. 13, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Restricted Share Units | 651 | $0.00 | 651.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 14, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Restricted Share Units | 851 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Restricted Share Units | 961 | $0.00 | 1,922.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 14, 2025 | Forminard Elizabeth | Executive VP, General Counsel | M | Performance Share Units | 1352 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 3470 | $0.00 | 393,444.0000 | 2,429,400,000 | 0.89% | 0.00% |
| Feb. 14, 2025 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 1510 | $155.26 | 391,934.0000 | 2,429,400,000 | 0.38% | 0.00% |
| Feb. 14, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 5053 | $0.00 | 396,987.0000 | 2,429,400,000 | 1.29% | 0.00% |
| Feb. 14, 2025 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 2198 | $156.71 | 394,789.0000 | 2,429,400,000 | 0.55% | 0.00% |
| Feb. 15, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 3682 | $0.00 | 398,471.0000 | 2,429,400,000 | 0.93% | 0.00% |
| Feb. 18, 2025 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 1602 | $156.15 | 396,869.0000 | 2,429,400,000 | 0.40% | 0.00% |
| Feb. 14, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 19282 | $0.00 | 416,151.0000 | 2,429,400,000 | 4.86% | 0.00% |
| Feb. 14, 2025 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 8386 | $156.71 | 407,765.0000 | 2,429,400,000 | 2.02% | 0.00% |
| Feb. 13, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 3470 | $0.00 | 3,469.0000 | 2,429,400,000 | 50.01% | 0.00% |
| Feb. 14, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 5053 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 3682 | $0.00 | 7,364.0000 | 2,429,400,000 | 33.33% | 0.00% |
| Feb. 14, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Performance Share Units | 19282 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2025 | Decker Robert J | VP Corporate Controller | M | Common Stock | 312 | $0.00 | 20,039.0000 | 2,429,400,000 | 1.58% | 0.00% |
| Feb. 14, 2025 | Decker Robert J | VP Corporate Controller | F | Common Stock | 104 | $155.26 | 19,935.0000 | 2,429,400,000 | 0.52% | 0.00% |
| Feb. 14, 2025 | Decker Robert J | VP Corporate Controller | M | Common Stock | 850 | $0.00 | 20,785.0000 | 2,429,400,000 | 4.26% | 0.00% |
| Feb. 14, 2025 | Decker Robert J | VP Corporate Controller | F | Common Stock | 254 | $156.71 | 20,531.0000 | 2,429,400,000 | 1.22% | 0.00% |
| Feb. 15, 2025 | Decker Robert J | VP Corporate Controller | M | Common Stock | 339 | $0.00 | 20,870.0000 | 2,429,400,000 | 1.65% | 0.00% |
| Feb. 18, 2025 | Decker Robert J | VP Corporate Controller | F | Common Stock | 94 | $156.15 | 20,776.0000 | 2,429,400,000 | 0.45% | 0.00% |
| Feb. 14, 2025 | Decker Robert J | VP Corporate Controller | M | Common Stock | 1351 | $0.00 | 22,127.0000 | 2,429,400,000 | 6.50% | 0.00% |
| Feb. 14, 2025 | Decker Robert J | VP Corporate Controller | F | Common Stock | 372 | $156.71 | 21,755.0000 | 2,429,400,000 | 1.68% | 0.00% |
| Feb. 13, 2025 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 312 | $0.00 | 312.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 14, 2025 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 850 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 339 | $0.00 | 677.0000 | 2,429,400,000 | 33.37% | 0.00% |
| Feb. 14, 2025 | Decker Robert J | VP Corporate Controller | M | Performance Share Units | 1351 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 13, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 408 | $0.00 | 20,242.0000 | 2,429,400,000 | 2.06% | 0.00% |
| Feb. 14, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 151 | $155.26 | 20,091.0000 | 2,429,400,000 | 0.75% | 0.00% |
| Feb. 14, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 1830 | $0.00 | 21,921.0000 | 2,429,400,000 | 9.11% | 0.00% |
| Feb. 14, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 574 | $156.71 | 21,347.0000 | 2,429,400,000 | 2.62% | 0.00% |
| Feb. 15, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 492 | $0.00 | 21,839.0000 | 2,429,400,000 | 2.30% | 0.00% |
| Feb. 18, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 158 | $156.15 | 21,681.0000 | 2,429,400,000 | 0.72% | 0.00% |
| Feb. 14, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 2910 | $0.00 | 24,591.0000 | 2,429,400,000 | 13.42% | 0.00% |
| Feb. 14, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 997 | $156.71 | 23,594.0000 | 2,429,400,000 | 4.05% | 0.00% |
| Feb. 13, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 408 | $0.00 | 408.0000 | 2,429,400,000 | 50.00% | 0.00% |
| Feb. 14, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 1830 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 14, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Performance Share Units | 2910 | $0.00 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 15, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 492 | $0.00 | 983.0000 | 2,429,400,000 | 33.36% | 0.00% |
| Feb. 10, 2025 | Swanson James D. | EVP, CIO | A | Performance Share Units | 3118 | $0.00 | 3,118.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Duato Joaquin | CEO and Chairman of the Board | A | Performance Share Units | 19282 | $0.00 | 19,282.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Performance Share Units | 2910 | $0.00 | 2,910.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Decker Robert J | VP Corporate Controller | A | Performance Share Units | 1351 | $0.00 | 1,351.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Forminard Elizabeth | Executive VP, General Counsel | A | Performance Share Units | 1352 | $0.00 | 1,352.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Wolk Joseph J | Exec VP, CFO | A | Performance Share Units | 15316 | $0.00 | 15,316.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Performance Share Units | 5837 | $0.00 | 5,837.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Mulholland Kristen | EVP, Chief HR Officer | A | Performance Share Units | 1601 | $0.00 | 1,601.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | Performance Share Units | 15465 | $0.00 | 15,465.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | A | Performance Share Units | 2806 | $0.00 | 2,806.0000 | 2,429,400,000 | 9999.99% | 0.00% |
| Feb. 7, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Employee Stock Options (Right to Buy) | 32762 | $100.06 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 7, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 47436 | $153.12 | 165,919.0010 | 2,429,400,000 | 22.23% | 0.00% |
| Feb. 7, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 58504 | $100.06 | 213,355.0010 | 2,429,400,000 | 37.78% | 0.00% |
| Feb. 7, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Employee Stock Options (Right to Buy) | 58504 | $100.06 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 7, 2025 | Wolk Joseph J | Exec VP, CFO | M | Employee Stock Options (Right to Buy) | 13015 | $100.06 | 0.0000 | 2,429,400,000 | 100.00% | 0.00% |
| Feb. 7, 2025 | Wolk Joseph J | Exec VP, CFO | S | Common Stock | 13015 | $153.89 | 70,948.0000 | 2,429,400,000 | 15.50% | 0.00% |
| Feb. 7, 2025 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 13015 | $100.06 | 83,963.0000 | 2,429,400,000 | 18.34% | 0.00% |
| Feb. 7, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 126369 | $100.06 | 490,617.0000 | 2,429,400,000 | 34.69% | 0.01% |
| Feb. 7, 2025 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 100643 | $153.12 | 389,974.0000 | 2,429,400,000 | 20.51% | 0.00% |
| Feb. 7, 2025 | Duato Joaquin | CEO and Chairman of the Board | M | Employee Stock Options (Right to Buy) | 126369 | $100.06 | 0.0000 | 2,429,400,000 | 100.00% | 0.01% |
| Feb. 7, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 32762 | $100.06 | 115,383.8735 | 2,429,400,000 | 39.65% | 0.00% |
| Feb. 7, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 26076 | $153.12 | 89,307.8735 | 2,429,400,000 | 22.60% | 0.00% |
| Dec. 12, 2024 | WEINBERGER MARK A | Director | P | Common Stock | 1000 | $147.22 | 1,000.0000 | 2,429,500,000 | 9999.99% | 0.00% |
| Dec. 10, 2024 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 335 | $149.67 | 11,380.2237 | 2,429,500,000 | 3.03% | 0.00% |
| Dec. 10, 2024 | Woods Eugene A. | Director | A | Deferred Share Units | 209 | $149.67 | 2,804.5872 | 2,429,500,000 | 8.04% | 0.00% |
| May 1, 2024 | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 10984 | $144.59 | 14,577.0000 | 2,560,400,000 | 42.97% | 0.00% |
| May 1, 2024 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 25255 | $0.00 | 50,510.0000 | 2,560,400,000 | 33.33% | 0.00% |
| May 1, 2024 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 25255 | $0.00 | 25,561.0000 | 2,560,400,000 | 8253.27% | 0.00% |
| May 22, 2024 | Wolk Joseph J | Exec VP, CFO | G | Common Stock | 55 | $0.00 | 139,765.0000 | 2,560,400,000 | 0.04% | 0.00% |
| Oct. 17, 2024 | Wolk Joseph J | Exec VP, CFO | G | Common Stock | 68835 | $0.00 | 70,930.0000 | 2,429,500,000 | 49.25% | 0.00% |
| Oct. 17, 2024 | Wolk Joseph J | Exec VP, CFO | G | Common Stock | 68835 | $0.00 | 70,930.0000 | 2,429,500,000 | 3285.68% | 0.00% |
| April 25, 2024 | DAVIS D SCOTT | Director | A | Deferred Share Units | 1386 | $0.00 | 15,603.6770 | 2,560,400,000 | 9.75% | 0.00% |
| Sept. 10, 2024 | Woods Eugene A. | Director | A | Deferred Share Units | 188 | $165.94 | 2,574.4652 | 2,560,400,000 | 7.89% | 0.00% |
| Sept. 10, 2024 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 303 | $165.94 | 10,954.9397 | 2,560,400,000 | 2.84% | 0.00% |
| Aug. 30, 2024 | Decker Robert J | VP Corporate Controller | M | Common Stock | 5635 | $100.06 | 25,356.0000 | 2,560,400,000 | 28.57% | 0.00% |
| Aug. 30, 2024 | Decker Robert J | VP Corporate Controller | S | Common Stock | 5635 | $165.06 | 19,721.0000 | 2,560,400,000 | 22.22% | 0.00% |
| Aug. 30, 2024 | Decker Robert J | VP Corporate Controller | M | Employee Stock Options (Right to Buy) | 5635 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| July 8, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 9809 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| July 8, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 9809 | $0.00 | 24,852.0000 | 2,560,400,000 | 65.21% | 0.00% |
| July 8, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 5018 | $147.16 | 19,834.0000 | 2,560,400,000 | 20.19% | 0.00% |
| June 4, 2024 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 315 | $147.85 | 10,573.3827 | 2,560,400,000 | 3.07% | 0.00% |
| June 4, 2024 | Woods Eugene A. | Director | A | Deferred Share Units | 211 | $147.85 | 2,368.4462 | 2,560,400,000 | 9.80% | 0.00% |
| May 1, 2024 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Common Stock | 22255 | $0.00 | 22,561.0000 | 2,560,400,000 | 7272.88% | 0.00% |
| May 1, 2024 | REED JOHN C | EVP, Innovative Medicine, R&D | F | Common Stock | 10984 | $144.59 | 11,577.0000 | 2,560,400,000 | 48.69% | 0.00% |
| May 1, 2024 | REED JOHN C | EVP, Innovative Medicine, R&D | M | Restricted Share Units | 22255 | $0.00 | 53,510.0000 | 2,560,400,000 | 29.37% | 0.00% |
| April 25, 2024 | Doudna Jennifer A | Director | A | Deferred Share Units | 1386 | $0.00 | 8,081.6380 | 2,560,400,000 | 20.69% | 0.00% |
| April 25, 2024 | Beckerle Mary C | Director | A | Deferred Share Units | 1386 | $0.00 | 13,643.0120 | 2,560,400,000 | 11.31% | 0.00% |
| April 25, 2024 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 1386 | $0.00 | 10,173.4414 | 2,560,400,000 | 15.77% | 0.00% |
| April 25, 2024 | West Nadja | Director | A | Deferred Share Units | 1386 | $0.00 | 5,093.6820 | 2,560,400,000 | 37.37% | 0.00% |
| April 25, 2024 | Adamczyk Darius | Director | A | Deferred Share Units | 1386 | $0.00 | 3,712.7040 | 2,560,400,000 | 59.55% | 0.00% |
| April 25, 2024 | Woods Eugene A. | Director | A | Deferred Share Units | 1386 | $0.00 | 2,139.1430 | 2,560,400,000 | 183.91% | 0.00% |
| April 25, 2024 | MULCAHY ANNE M | Director | A | Deferred Share Units | 1386 | $0.00 | 21,470.6180 | 2,560,400,000 | 6.90% | 0.00% |
| April 25, 2024 | WEINBERGER MARK A | Director | A | Deferred Share Units | 1386 | $0.00 | 9,129.3520 | 2,560,400,000 | 17.89% | 0.00% |
| April 25, 2024 | McClellan Mark B. | Director | A | Deferred Share Units | 1386 | $0.00 | 17,867.7150 | 2,560,400,000 | 8.41% | 0.00% |
| April 25, 2024 | Joly Hubert | Director | A | Deferred Share Units | 1386 | $0.00 | 6,464.1450 | 2,560,400,000 | 27.29% | 0.00% |
| April 25, 2024 | Johnson Paula A | Director | A | Deferred Share Units | 1386 | $0.00 | 2,858.5480 | 2,560,400,000 | 94.08% | 0.00% |
| March 13, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | S | Common Stock | 8891 | $162.16 | 15,043.0000 | 2,560,400,000 | 37.15% | 0.00% |
| March 5, 2024 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 235 | $159.80 | 8,787.7444 | 2,560,400,000 | 2.74% | 0.00% |
| March 5, 2024 | Woods Eugene A. | Director | A | Deferred Share Units | 262 | $159.80 | 753.4460 | 2,560,400,000 | 53.31% | 0.00% |
| March 5, 2024 | Woods Eugene A. | Director | A | Deferred Share Units | 491 | $159.80 | 491.4530 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 79 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 16, 2024 | JOHNSON & JOHNSON | Not found | X | Common Stock | 607725 | $0.16 | 4,103,300.0000 | 2,560,400,000 | 17.39% | 0.02% |
| Feb. 16, 2024 | JOHNSON & JOHNSON | Not found | S | Common Stock | 3725 | $25.81 | 4,099,575.0000 | 2,560,400,000 | 0.09% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 158 | $0.24 | 4,099,733.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 189 | $0.24 | 4,099,922.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 165 | $0.24 | 4,100,087.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 118 | $0.24 | 4,100,205.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 71 | $0.24 | 4,100,276.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 23 | $0.24 | 4,100,299.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 85 | $0.24 | 4,100,384.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 758 | $0.24 | 4,101,142.0000 | 2,560,400,000 | 0.02% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 489 | $0.24 | 4,101,631.0000 | 2,560,400,000 | 0.01% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 584 | $0.24 | 4,102,215.0000 | 2,560,400,000 | 0.01% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 300 | $0.24 | 4,102,515.0000 | 2,560,400,000 | 0.01% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 442 | $1.19 | 4,102,957.0000 | 2,560,400,000 | 0.01% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 142 | $1.19 | 4,103,099.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 252 | $3.96 | 4,103,351.0000 | 2,560,400,000 | 0.01% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Common Stock | 79 | $5.14 | 4,103,430.0000 | 2,560,400,000 | 0.00% | 0.00% |
| Feb. 16, 2024 | JOHNSON & JOHNSON | Not found | X | Warrant to Purchase Common Stock | 607225 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.02% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 158 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 189 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 165 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 118 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 71 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 23 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 85 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 758 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 489 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 584 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 300 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 442 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 142 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 29, 2024 | JOHNSON & JOHNSON | Not found | M | Stock Option (Right to Buy) | 252 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 15, 2024 | Swanson James D. | EVP, CIO | A | Employee Stock Options (Right to Buy) | 23745 | $0.00 | 23,745.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Swanson James D. | EVP, CIO | A | Restricted Share Units | 1475 | $0.00 | 1,475.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | REED JOHN C | EVP, Innovative Medicine, R&D | A | Employee Stock Options (Right to Buy) | 65163 | $0.00 | 65,163.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | REED JOHN C | EVP, Innovative Medicine, R&D | A | Restricted Share Units | 4048 | $0.00 | 4,048.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Wolk Joseph J | Exec VP, CFO | A | Employee Stock Options (Right to Buy) | 95197 | $0.00 | 95,197.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Wolk Joseph J | Exec VP, CFO | A | Restricted Share Units | 5913 | $0.00 | 5,913.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Forminard Elizabeth | Executive VP, General Counsel | A | Employee Stock Options (Right to Buy) | 46406 | $0.00 | 46,406.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Forminard Elizabeth | Executive VP, General Counsel | A | Restricted Share Units | 2883 | $0.00 | 2,883.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Duato Joaquin | CEO and Chairman of the Board | A | Employee Stock Options (Right to Buy) | 177816 | $0.00 | 177,816.0000 | 2,560,400,000 | 9999.99% | 0.01% |
| Feb. 15, 2024 | Duato Joaquin | CEO and Chairman of the Board | A | Restricted Share Units | 11046 | $0.00 | 11,046.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | A | Employee Stock Options (Right to Buy) | 40551 | $0.00 | 40,551.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | A | Restricted Share Units | 2519 | $0.00 | 2,519.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Employee Stock Options (Right to Buy) | 23745 | $0.00 | 23,745.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Restricted Share Units | 1475 | $0.00 | 1,475.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Decker Robert J | VP Corporate Controller | A | Employee Stock Options (Right to Buy) | 8175 | $0.00 | 8,175.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Decker Robert J | VP Corporate Controller | A | Restricted Share Units | 1016 | $0.00 | 1,016.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | Employee Stock Options (Right to Buy) | 76981 | $0.00 | 76,981.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | A | Restricted Share Units | 4782 | $0.00 | 4,782.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Employee Stock Options (Right to Buy) | 29275 | $0.00 | 29,275.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Restricted Share Units | 1819 | $0.00 | 1,819.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | A | Employee Stock Options (Right to Buy) | 49658 | $0.00 | 49,658.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | A | Restricted Share Units | 3085 | $0.00 | 3,085.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Hait William | EVP, Chief EI and Med Officer | A | Employee Stock Options (Right to Buy) | 34696 | $0.00 | 34,696.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 15, 2024 | Hait William | EVP, Chief EI and Med Officer | A | Restricted Share Units | 2155 | $0.00 | 2,155.0000 | 2,560,400,000 | 9999.99% | 0.00% |
| Feb. 13, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 3470 | $0.00 | 6,939.0000 | 2,560,400,000 | 33.34% | 0.00% |
| Feb. 13, 2024 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 651 | $0.00 | 8,576.0000 | 2,560,400,000 | 8.21% | 0.00% |
| Feb. 13, 2024 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 236 | $157.85 | 8,340.0000 | 2,560,400,000 | 2.75% | 0.00% |
| Feb. 13, 2024 | Forminard Elizabeth | Executive VP, General Counsel | M | Restricted Share Units | 651 | $0.00 | 1,302.0000 | 2,560,400,000 | 33.33% | 0.00% |
| Feb. 13, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 408 | $0.00 | 24,143.0000 | 2,560,400,000 | 1.72% | 0.00% |
| Feb. 13, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 209 | $157.85 | 23,934.0000 | 2,560,400,000 | 0.87% | 0.00% |
| Feb. 13, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 408 | $0.00 | 816.0000 | 2,560,400,000 | 33.33% | 0.00% |
| Feb. 13, 2024 | Decker Robert J | VP Corporate Controller | M | Common Stock | 313 | $0.00 | 19,790.0000 | 2,560,400,000 | 1.61% | 0.00% |
| Feb. 13, 2024 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 313 | $0.00 | 624.0000 | 2,560,400,000 | 33.40% | 0.00% |
| Feb. 13, 2024 | Decker Robert J | VP Corporate Controller | F | Common Stock | 86 | $157.85 | 19,704.0000 | 2,560,400,000 | 0.43% | 0.00% |
| Feb. 13, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 651 | $0.00 | 82,943.8735 | 2,560,400,000 | 0.79% | 0.00% |
| Feb. 13, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 333 | $157.85 | 82,610.8735 | 2,560,400,000 | 0.40% | 0.00% |
| Feb. 13, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 651 | $0.00 | 1,302.0000 | 2,560,400,000 | 33.33% | 0.00% |
| Feb. 13, 2024 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 1780 | $0.00 | 71,711.0000 | 2,560,400,000 | 2.55% | 0.00% |
| Feb. 13, 2024 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 773 | $157.85 | 70,938.0000 | 2,560,400,000 | 1.08% | 0.00% |
| Feb. 13, 2024 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 1780 | $0.00 | 3,558.0000 | 2,560,400,000 | 33.35% | 0.00% |
| Feb. 13, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 1302 | $0.00 | 155,517.0010 | 2,560,400,000 | 0.84% | 0.00% |
| Feb. 13, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 666 | $157.85 | 154,851.0010 | 2,560,400,000 | 0.43% | 0.00% |
| Feb. 13, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Restricted Share Units | 1302 | $0.00 | 2,604.0000 | 2,560,400,000 | 33.33% | 0.00% |
| Feb. 13, 2024 | Swanson James D. | EVP, CIO | M | Common Stock | 447 | $0.00 | 14,765.0000 | 2,560,400,000 | 3.12% | 0.00% |
| Feb. 13, 2024 | Swanson James D. | EVP, CIO | F | Common Stock | 195 | $157.85 | 14,570.0000 | 2,560,400,000 | 1.32% | 0.00% |
| Feb. 13, 2024 | Swanson James D. | EVP, CIO | M | Restricted Share Units | 447 | $0.00 | 894.0000 | 2,560,400,000 | 33.33% | 0.00% |
| Feb. 13, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 499 | $0.00 | 14,036.0000 | 2,560,400,000 | 3.69% | 0.00% |
| Feb. 13, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 250 | $157.85 | 13,786.0000 | 2,560,400,000 | 1.78% | 0.00% |
| Feb. 13, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | M | Restricted Share Units | 499 | $0.00 | 998.0000 | 2,560,400,000 | 33.33% | 0.00% |
| Feb. 13, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | M | Common Stock | 925 | $0.00 | 112,550.0000 | 2,560,400,000 | 0.83% | 0.00% |
| Feb. 13, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | F | Common Stock | 474 | $157.85 | 112,076.0000 | 2,560,400,000 | 0.42% | 0.00% |
| Feb. 13, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | M | Restricted Share Units | 925 | $0.00 | 1,848.0000 | 2,560,400,000 | 33.36% | 0.00% |
| Feb. 13, 2024 | Hait William | See Remarks | M | Common Stock | 834 | $0.00 | 39,074.0000 | 2,560,400,000 | 2.18% | 0.00% |
| Feb. 13, 2024 | Hait William | See Remarks | F | Common Stock | 427 | $157.85 | 38,647.0000 | 2,560,400,000 | 1.09% | 0.00% |
| Feb. 13, 2024 | Hait William | See Remarks | M | Restricted Share Units | 834 | $0.00 | 1,666.0000 | 2,560,400,000 | 33.36% | 0.00% |
| Feb. 13, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 3470 | $0.00 | 365,692.0000 | 2,560,400,000 | 0.96% | 0.00% |
| Feb. 13, 2024 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 1507 | $157.85 | 364,185.0000 | 2,560,400,000 | 0.41% | 0.00% |
| Feb. 12, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 31351 | $0.00 | 372,855.0000 | 2,560,400,000 | 9.18% | 0.00% |
| Feb. 12, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Performance Share Units | 11826 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 7066 | $157.40 | 82,292.8735 | 2,560,400,000 | 7.91% | 0.00% |
| Feb. 12, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 1987 | $0.00 | 89,358.8735 | 2,560,400,000 | 2.27% | 0.00% |
| Feb. 12, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 11826 | $0.00 | 87,371.8735 | 2,560,400,000 | 15.65% | 0.00% |
| Feb. 12, 2024 | Decker Robert J | VP Corporate Controller | M | Performance Share Units | 1637 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Decker Robert J | VP Corporate Controller | F | Common Stock | 523 | $157.40 | 19,477.0000 | 2,560,400,000 | 2.62% | 0.00% |
| Feb. 12, 2024 | Decker Robert J | VP Corporate Controller | M | Common Stock | 275 | $0.00 | 20,000.0000 | 2,560,400,000 | 1.39% | 0.00% |
| Feb. 12, 2024 | Decker Robert J | VP Corporate Controller | M | Common Stock | 1637 | $0.00 | 19,725.0000 | 2,560,400,000 | 9.05% | 0.00% |
| Feb. 12, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | M | Performance Share Units | 4911 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 2887 | $157.40 | 13,537.0000 | 2,560,400,000 | 17.58% | 0.00% |
| Feb. 12, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 825 | $0.00 | 16,424.0000 | 2,560,400,000 | 5.29% | 0.00% |
| Feb. 12, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 4911 | $0.00 | 15,599.0000 | 2,560,400,000 | 45.95% | 0.00% |
| Feb. 12, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Performance Share Units | 31351 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 15900 | $157.40 | 362,222.0000 | 2,560,400,000 | 4.20% | 0.00% |
| Feb. 12, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 5267 | $0.00 | 378,122.0000 | 2,560,400,000 | 1.41% | 0.00% |
| Feb. 12, 2024 | Swanson James D. | EVP, CIO | M | Performance Share Units | 4671 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Swanson James D. | EVP, CIO | F | Common Stock | 1695 | $157.40 | 14,318.0000 | 2,560,400,000 | 10.59% | 0.00% |
| Feb. 12, 2024 | Swanson James D. | EVP, CIO | M | Common Stock | 785 | $0.00 | 16,013.0000 | 2,560,400,000 | 5.15% | 0.00% |
| Feb. 12, 2024 | Swanson James D. | EVP, CIO | M | Common Stock | 4671 | $0.00 | 15,228.0000 | 2,560,400,000 | 44.25% | 0.00% |
| Feb. 12, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | M | Performance Share Units | 12808 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | F | Common Stock | 7019 | $157.40 | 111,625.0000 | 2,560,400,000 | 5.92% | 0.00% |
| Feb. 12, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | M | Common Stock | 2152 | $0.00 | 118,644.0000 | 2,560,400,000 | 1.85% | 0.00% |
| Feb. 12, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | M | Common Stock | 12808 | $0.00 | 116,492.0000 | 2,560,400,000 | 12.35% | 0.00% |
| Feb. 12, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Performance Share Units | 22433 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F | Common Stock | 13403 | $157.40 | 154,215.0010 | 2,560,400,000 | 8.00% | 0.00% |
| Feb. 12, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 3769 | $0.00 | 167,618.0010 | 2,560,400,000 | 2.30% | 0.00% |
| Feb. 12, 2024 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M | Common Stock | 22433 | $0.00 | 163,849.0010 | 2,560,400,000 | 15.86% | 0.00% |
| Feb. 12, 2024 | Forminard Elizabeth | Executive VP, General Counsel | M | Performance Share Units | 2448 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 1034 | $157.40 | 7,925.0000 | 2,560,400,000 | 11.54% | 0.00% |
| Feb. 12, 2024 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 411 | $0.00 | 8,959.0000 | 2,560,400,000 | 4.81% | 0.00% |
| Feb. 12, 2024 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 2448 | $0.00 | 8,548.0000 | 2,560,400,000 | 40.13% | 0.00% |
| Feb. 12, 2024 | Wolk Joseph J | Exec VP, CFO | M | Performance Share Units | 22119 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 10816 | $157.40 | 69,931.0000 | 2,560,400,000 | 13.39% | 0.00% |
| Feb. 12, 2024 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 3716 | $0.00 | 80,747.0000 | 2,560,400,000 | 4.82% | 0.00% |
| Feb. 12, 2024 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 22119 | $0.00 | 77,031.0000 | 2,560,400,000 | 40.28% | 0.00% |
| Feb. 12, 2024 | Hait William | See Remarks | M | Performance Share Units | 7647 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Hait William | See Remarks | F | Common Stock | 4076 | $157.40 | 38,240.0000 | 2,560,400,000 | 9.63% | 0.00% |
| Feb. 12, 2024 | Hait William | See Remarks | M | Common Stock | 1285 | $0.00 | 42,316.0000 | 2,560,400,000 | 3.13% | 0.00% |
| Feb. 12, 2024 | Hait William | See Remarks | M | Common Stock | 7647 | $0.00 | 41,031.0000 | 2,560,400,000 | 22.91% | 0.00% |
| Feb. 12, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Performance Share Units | 4701 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 12, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 2136 | $157.40 | 23,735.0000 | 2,560,400,000 | 8.26% | 0.00% |
| Feb. 12, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Common Stock | 790 | $0.00 | 25,871.0000 | 2,560,400,000 | 3.15% | 0.00% |
| Feb. 12, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 4701 | $0.00 | 25,081.0000 | 2,560,400,000 | 23.07% | 0.00% |
| Feb. 9, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Employee Stock Options (Right to Buy) | 130969 | $90.44 | 0.0000 | 2,560,400,000 | 100.00% | 0.01% |
| Feb. 9, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 35638 | $90.44 | 102,878.8735 | 2,560,400,000 | 53.00% | 0.00% |
| Feb. 9, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 27333 | $156.76 | 75,545.8735 | 2,560,400,000 | 26.57% | 0.00% |
| Feb. 9, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Employee Stock Options (Right to Buy) | 35638 | $90.44 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 9, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 130969 | $90.44 | 440,166.0000 | 2,560,400,000 | 42.36% | 0.01% |
| Feb. 9, 2024 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 98662 | $156.76 | 341,504.0000 | 2,560,400,000 | 22.41% | 0.00% |
| Feb. 8, 2024 | Hait William | See Remarks | M | Restricted Share Units | 3059 | $0.00 | 3,059.0000 | 2,560,400,000 | 50.00% | 0.00% |
| Feb. 8, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 1880 | $0.00 | 21,083.0000 | 2,560,400,000 | 9.79% | 0.00% |
| Feb. 8, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 703 | $156.33 | 20,380.0000 | 2,560,400,000 | 3.33% | 0.00% |
| Feb. 8, 2024 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 1880 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Decker Robert J | VP Corporate Controller | M | Common Stock | 655 | $0.00 | 18,303.0000 | 2,560,400,000 | 3.71% | 0.00% |
| Feb. 8, 2024 | Decker Robert J | VP Corporate Controller | F | Common Stock | 215 | $156.33 | 18,088.0000 | 2,560,400,000 | 1.17% | 0.00% |
| Feb. 8, 2024 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 2269 | $156.33 | 309,197.0000 | 2,560,400,000 | 0.73% | 0.00% |
| Feb. 8, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 5225 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 1971 | $0.00 | 68,249.8735 | 2,560,400,000 | 2.97% | 0.00% |
| Feb. 8, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 1009 | $156.33 | 67,240.8735 | 2,560,400,000 | 1.48% | 0.00% |
| Feb. 8, 2024 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 1971 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 3686 | $0.00 | 55,959.0000 | 2,560,400,000 | 7.05% | 0.00% |
| Feb. 8, 2024 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 1047 | $156.33 | 54,912.0000 | 2,560,400,000 | 1.87% | 0.00% |
| Feb. 8, 2024 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 3686 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 979 | $0.00 | 6,463.0000 | 2,560,400,000 | 17.85% | 0.00% |
| Feb. 8, 2024 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 363 | $156.33 | 6,100.0000 | 2,560,400,000 | 5.62% | 0.00% |
| Feb. 8, 2024 | Forminard Elizabeth | Executive VP, General Counsel | M | Restricted Share Units | 979 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Swanson James D. | See Remarks | M | Common Stock | 1868 | $0.00 | 11,111.0000 | 2,560,400,000 | 20.21% | 0.00% |
| Feb. 8, 2024 | Swanson James D. | See Remarks | F | Common Stock | 554 | $156.33 | 10,557.0000 | 2,560,400,000 | 4.99% | 0.00% |
| Feb. 8, 2024 | Swanson James D. | See Remarks | M | Restricted Share Units | 1868 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | M | Common Stock | 1964 | $0.00 | 11,689.0000 | 2,560,400,000 | 20.20% | 0.00% |
| Feb. 8, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | F | Common Stock | 1001 | $156.33 | 10,688.0000 | 2,560,400,000 | 8.56% | 0.00% |
| Feb. 8, 2024 | Schmid Timothy | EVP, WW Chair, MedTech | M | Restricted Share Units | 1964 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | M | Common Stock | 2135 | $0.00 | 104,465.0000 | 2,560,400,000 | 2.09% | 0.00% |
| Feb. 9, 2024 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | M | Employee Stock Options (Right to Buy) | 59397 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 655 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | F | Common Stock | 781 | $156.33 | 103,684.0000 | 2,560,400,000 | 0.75% | 0.00% |
| Feb. 8, 2024 | Fasolo Peter | Exec VP, Chief HR Officer | M | Restricted Share Units | 2135 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Feb. 8, 2024 | Hait William | See Remarks | M | Common Stock | 3059 | $0.00 | 34,497.0000 | 2,560,400,000 | 9.73% | 0.00% |
| Feb. 8, 2024 | Hait William | See Remarks | F | Common Stock | 1113 | $156.33 | 33,384.0000 | 2,560,400,000 | 3.23% | 0.00% |
| Feb. 8, 2024 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 5225 | $0.00 | 311,466.0000 | 2,560,400,000 | 1.71% | 0.00% |
| Feb. 8, 2024 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | M | Common Stock | 3739 | $0.00 | 143,329.0010 | 2,560,400,000 | 2.68% | 0.00% |
| Feb. 8, 2024 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | F | Common Stock | 1913 | $156.33 | 141,416.0010 | 2,560,400,000 | 1.33% | 0.00% |
| Feb. 9, 2024 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | M | Common Stock | 59397 | $90.44 | 200,813.0010 | 2,560,400,000 | 42.00% | 0.00% |
| Feb. 9, 2024 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | S | Common Stock | 59397 | $156.27 | 141,416.0010 | 2,560,400,000 | 29.58% | 0.00% |
| Feb. 8, 2024 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | M | Restricted Share Units | 3739 | $0.00 | 0.0000 | 2,560,400,000 | 100.00% | 0.00% |
| Dec. 5, 2023 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 228 | $159.01 | 8,489.8531 | 2,663,900,000 | 2.76% | 0.00% |
| Sept. 7, 2023 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 229 | $158.63 | 8,200.5090 | 2,663,900,000 | 2.87% | 0.00% |
| Aug. 23, 2023 | Duato Joaquin | CEO and Chairman of the Board | D | Common Stock | 11035 | $0.00 | 306,217.0000 | 2,663,900,000 | 3.48% | 0.00% |
| Aug. 23, 2023 | Wolk Joseph J | Exec VP, CFO | D | Common Stock | 67 | $0.00 | 52,293.2040 | 2,663,900,000 | 0.13% | 0.00% |
| Aug. 23, 2023 | JOHNSON & JOHNSON | TenPercentOwner | J | Common Stock | 1533830450 | $0.00 | 182,329,550.0000 | 2,663,900,000 | 89.38% | 57.58% |
| Aug. 23, 2023 | Hait William | See Remarks | D | Common Stock | 696 | $0.00 | 87,051.0000 | 2,663,900,000 | 0.79% | 0.00% |
| Aug. 23, 2023 | McEvoy Ashley | EVP, WW Chair, MedTech | D | Common Stock | 2787 | $0.00 | 55,143.9545 | 2,663,900,000 | 4.81% | 0.00% |
| Aug. 23, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | D | Common Stock | 232 | $0.00 | 102,464.0055 | 2,663,900,000 | 0.23% | 0.00% |
| July 26, 2023 | Hait William | See Remarks | M | Common Stock | 14698 | $90.44 | 102,445.0000 | 2,663,900,000 | 16.75% | 0.00% |
| July 26, 2023 | Hait William | See Remarks | M | Employee Stock Options (Right to Buy) | 14698 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| July 25, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | S | Common Stock | 20000 | $170.32 | 102,696.0055 | 2,663,900,000 | 16.30% | 0.00% |
| July 26, 2023 | Hait William | See Remarks | S | Common Stock | 14698 | $172.00 | 87,747.0000 | 2,663,900,000 | 14.35% | 0.00% |
| June 12, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | S | Common Stock | 12465 | $160.00 | 66,273.8735 | 2,663,900,000 | 15.83% | 0.00% |
| June 6, 2023 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 230 | $157.52 | 7,912.6320 | 2,663,900,000 | 3.00% | 0.00% |
| May 24, 2023 | Wolk Joseph J | Exec VP, CFO | G | Common Stock | 55 | $0.00 | 52,345.2040 | 2,663,900,000 | 0.10% | 0.00% |
| April 27, 2023 | Joly Hubert | Director | A | Deferred Share Units | 1194 | $0.00 | 4,928.9730 | 2,663,900,000 | 31.97% | 0.00% |
| April 27, 2023 | McClellan Mark B. | Director | A | Deferred Share Units | 1194 | $0.00 | 15,996.8990 | 2,663,900,000 | 8.07% | 0.00% |
| May 1, 2023 | REED JOHN C | EVP, Pharmaceuticals R&D | A | Restricted Share Units | 75765 | $0.00 | 75,765.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| April 27, 2023 | West Nadja | Director | A | Deferred Share Units | 1194 | $0.00 | 3,598.8460 | 2,663,900,000 | 49.65% | 0.00% |
| April 27, 2023 | WEINBERGER MARK A | Director | A | Deferred Share Units | 1194 | $0.00 | 7,515.7340 | 2,663,900,000 | 18.89% | 0.00% |
| April 27, 2023 | MULCAHY ANNE M | Director | A | Deferred Share Units | 1194 | $0.00 | 19,493.7570 | 2,663,900,000 | 6.52% | 0.00% |
| April 27, 2023 | Johnson Paula A | Director | A | Deferred Share Units | 1430 | $0.00 | 1,429.5000 | 2,663,900,000 | 9999.99% | 0.00% |
| April 27, 2023 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 1194 | $0.00 | 7,624.9000 | 2,663,900,000 | 18.57% | 0.00% |
| April 27, 2023 | Doudna Jennifer A | Director | A | Deferred Share Units | 1194 | $0.00 | 6,498.8580 | 2,663,900,000 | 22.51% | 0.00% |
| April 27, 2023 | Beckerle Mary C | Director | A | Deferred Share Units | 1194 | $0.00 | 11,896.5420 | 2,663,900,000 | 11.16% | 0.00% |
| April 27, 2023 | DAVIS D SCOTT | Director | A | Deferred Share Units | 1194 | $0.00 | 13,799.4980 | 2,663,900,000 | 9.47% | 0.00% |
| April 27, 2023 | Adamczyk Darius | Director | A | Deferred Share Units | 1194 | $0.00 | 2,258.5150 | 2,663,900,000 | 112.16% | 0.00% |
| March 7, 2023 | Washington A. Eugene | Director | A | Deferred Share Units | 201 | $155.16 | 28,569.4483 | 2,663,900,000 | 0.71% | 0.00% |
| March 7, 2023 | HEWSON MARILLYN A | Director | A | Deferred Share Units | 234 | $155.16 | 6,430.9250 | 2,663,900,000 | 3.77% | 0.00% |
| March 6, 2023 | Swanson James D. | See Remarks | S | Common Stock | 1062 | $154.66 | 9,215.3198 | 2,663,900,000 | 10.33% | 0.00% |
| Feb. 13, 2023 | Wolk Joseph J | Exec VP, CFO | A | Restricted Share Units | 5338 | $0.00 | 5,338.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Common Stock | 3981 | $0.00 | 20,643.0000 | 2,663,900,000 | 23.89% | 0.00% |
| Feb. 13, 2023 | Forminard Elizabeth | Executive VP, General Counsel | A | Restricted Share Units | 1953 | $0.00 | 1,953.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Forminard Elizabeth | Executive VP, General Counsel | A | Employee Stock Options (Right to Buy) | 32317 | $0.00 | 32,317.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 924 | $162.01 | 5,484.0000 | 2,663,900,000 | 14.42% | 0.00% |
| Feb. 13, 2023 | Forminard Elizabeth | Executive VP, General Counsel | A | Common Stock | 2555 | $0.00 | 6,408.0000 | 2,663,900,000 | 66.31% | 0.00% |
| Feb. 13, 2023 | Decker Robert J | VP Corporate Controller | A | Restricted Share Units | 937 | $0.00 | 937.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Decker Robert J | VP Corporate Controller | A | Employee Stock Options (Right to Buy) | 7756 | $0.00 | 7,756.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Decker Robert J | VP Corporate Controller | F | Common Stock | 397 | $162.01 | 17,627.0000 | 2,663,900,000 | 2.20% | 0.00% |
| Feb. 13, 2023 | Decker Robert J | VP Corporate Controller | A | Common Stock | 1451 | $0.00 | 18,024.0000 | 2,663,900,000 | 8.76% | 0.00% |
| Feb. 13, 2023 | Duato Joaquin | CEO and Chairman of the Board | A | Restricted Share Units | 10409 | $0.00 | 10,409.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Duato Joaquin | CEO and Chairman of the Board | A | Employee Stock Options (Right to Buy) | 172250 | $0.00 | 172,250.0000 | 2,663,900,000 | 9999.99% | 0.01% |
| Feb. 13, 2023 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 13599 | $162.01 | 317,222.0000 | 2,663,900,000 | 4.11% | 0.00% |
| Feb. 13, 2023 | Duato Joaquin | CEO and Chairman of the Board | A | Common Stock | 31319 | $0.00 | 330,821.0000 | 2,663,900,000 | 10.46% | 0.00% |
| Feb. 13, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | A | Restricted Share Units | 2773 | $0.00 | 2,773.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | A | Employee Stock Options (Right to Buy) | 45890 | $0.00 | 45,890.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | F | Common Stock | 5765 | $162.01 | 122,696.0055 | 2,663,900,000 | 4.49% | 0.00% |
| Feb. 13, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | A | Common Stock | 12468 | $0.00 | 128,461.0055 | 2,663,900,000 | 10.75% | 0.00% |
| Feb. 13, 2023 | Hait William | See Remarks | A | Restricted Share Units | 2500 | $0.00 | 2,500.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Hait William | See Remarks | A | Employee Stock Options (Right to Buy) | 41366 | $0.00 | 41,366.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Hait William | See Remarks | F | Common Stock | 4586 | $162.01 | 87,747.0000 | 2,663,900,000 | 4.97% | 0.00% |
| Feb. 13, 2023 | Hait William | See Remarks | A | Common Stock | 9640 | $0.00 | 92,333.0000 | 2,663,900,000 | 11.66% | 0.00% |
| Feb. 13, 2023 | McEvoy Ashley | EVP, WW Chair, MedTech | A | Restricted Share Units | 3704 | $0.00 | 3,704.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | McEvoy Ashley | EVP, WW Chair, MedTech | A | Employee Stock Options (Right to Buy) | 61295 | $0.00 | 61,295.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | McEvoy Ashley | EVP, WW Chair, MedTech | F | Common Stock | 7158 | $162.01 | 57,847.9545 | 2,663,900,000 | 11.01% | 0.00% |
| Feb. 13, 2023 | McEvoy Ashley | EVP, WW Chair, MedTech | A | Common Stock | 17994 | $0.00 | 65,005.9545 | 2,663,900,000 | 38.28% | 0.00% |
| Feb. 13, 2023 | Mongon Thibaut | Exec VP, WW Chair, Cons Health | A | Restricted Share Units | 3417 | $0.00 | 3,417.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Mongon Thibaut | Exec VP, WW Chair, Cons Health | A | Employee Stock Options (Right to Buy) | 56555 | $0.00 | 56,555.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Mongon Thibaut | Exec VP, WW Chair, Cons Health | F | Common Stock | 6430 | $162.01 | 65,915.2661 | 2,663,900,000 | 8.89% | 0.00% |
| Feb. 13, 2023 | Mongon Thibaut | Exec VP, WW Chair, Cons Health | A | Common Stock | 13710 | $0.00 | 72,345.2661 | 2,663,900,000 | 23.38% | 0.00% |
| Feb. 13, 2023 | Swanson James D. | See Remarks | A | Restricted Share Units | 1341 | $0.00 | 1,341.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Swanson James D. | See Remarks | A | Employee Stock Options (Right to Buy) | 22191 | $0.00 | 22,191.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Swanson James D. | See Remarks | F | Common Stock | 918 | $162.01 | 10,277.0000 | 2,663,900,000 | 8.20% | 0.00% |
| Feb. 13, 2023 | Swanson James D. | See Remarks | A | Common Stock | 3228 | $0.00 | 11,195.0000 | 2,663,900,000 | 40.52% | 0.00% |
| Feb. 13, 2023 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | A | Restricted Share Units | 3906 | $0.00 | 3,906.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | A | Employee Stock Options (Right to Buy) | 64634 | $0.00 | 64,634.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | F | Common Stock | 10569 | $162.01 | 139,590.0010 | 2,663,900,000 | 7.04% | 0.00% |
| Feb. 13, 2023 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | A | Common Stock | 21422 | $0.00 | 150,159.0010 | 2,663,900,000 | 16.64% | 0.00% |
| Feb. 13, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Restricted Share Units | 1953 | $0.00 | 1,953.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Employee Stock Options (Right to Buy) | 32317 | $0.00 | 32,317.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 4891 | $162.01 | 78,733.8735 | 2,663,900,000 | 5.85% | 0.00% |
| Feb. 13, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | A | Common Stock | 10839 | $0.00 | 83,624.8735 | 2,663,900,000 | 14.89% | 0.00% |
| Feb. 13, 2023 | Wolk Joseph J | Exec VP, CFO | A | Employee Stock Options (Right to Buy) | 88334 | $0.00 | 88,334.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 8578 | $162.01 | 52,385.2040 | 2,663,900,000 | 14.07% | 0.00% |
| Feb. 13, 2023 | Wolk Joseph J | Exec VP, CFO | A | Common Stock | 20693 | $0.00 | 60,963.2040 | 2,663,900,000 | 51.39% | 0.00% |
| Feb. 13, 2023 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Restricted Share Units | 1224 | $0.00 | 1,224.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Broadhurst Vanessa | EVP, Global Corp Affairs | A | Employee Stock Options (Right to Buy) | 20263 | $0.00 | 20,263.0000 | 2,663,900,000 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 1440 | $162.01 | 19,203.0000 | 2,663,900,000 | 6.98% | 0.00% |
| Feb. 10, 2023 | Decker Robert J | VP Corporate Controller | F | Common Stock | 191 | $162.08 | 16,573.0000 | 2,663,900,000 | 1.14% | 0.00% |
| Feb. 10, 2023 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 5220 | $0.00 | 301,769.0000 | 2,663,900,000 | 1.76% | 0.00% |
| Feb. 10, 2023 | Decker Robert J | VP Corporate Controller | M | Restricted Share Units | 581 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Common Stock | 1592 | $0.00 | 17,259.0000 | 2,663,900,000 | 10.16% | 0.00% |
| Feb. 10, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | F | Common Stock | 761 | $162.08 | 115,993.0055 | 2,663,900,000 | 0.65% | 0.00% |
| Feb. 10, 2023 | Broadhurst Vanessa | EVP, Global Corp Affairs | F | Common Stock | 597 | $162.08 | 16,662.0000 | 2,663,900,000 | 3.46% | 0.00% |
| Feb. 10, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | M | Restricted Share Units | 2078 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Swanson James D. | See Remarks | M | Common Stock | 1291 | $0.00 | 8,355.0000 | 2,663,900,000 | 18.28% | 0.00% |
| Feb. 10, 2023 | Swanson James D. | See Remarks | F | Common Stock | 388 | $162.08 | 7,967.0000 | 2,663,900,000 | 4.64% | 0.00% |
| Feb. 14, 2022 | Swanson James D. | See Remarks | A | Employee Stock Options (Right to Buy) | 19368 | $165.89 | 19,368.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2022 | Swanson James D. | See Remarks | A | Restricted Share Units | 1961 | $0.00 | 1,961.0000 | 0 | 9999.99% | 0.00% |
| Feb. 10, 2023 | Swanson James D. | See Remarks | M | Restricted Share Units | 1291 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Hait William | See Remarks | F | Common Stock | 1399 | $162.08 | 82,693.0000 | 2,663,900,000 | 1.66% | 0.00% |
| Feb. 10, 2023 | Mongon Thibaut | Exec VP, WW Chair, Cons Health | M | Common Stock | 2285 | $0.00 | 59,461.2661 | 2,663,900,000 | 4.00% | 0.00% |
| Feb. 10, 2023 | Mongon Thibaut | Exec VP, WW Chair, Cons Health | F | Common Stock | 826 | $162.08 | 58,635.2661 | 2,663,900,000 | 1.39% | 0.00% |
| Feb. 10, 2023 | Mongon Thibaut | Exec VP, WW Chair, Cons Health | M | Restricted Share Units | 2285 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Decker Robert J | VP Corporate Controller | M | Common Stock | 581 | $0.00 | 16,764.0000 | 2,663,900,000 | 3.59% | 0.00% |
| Feb. 10, 2023 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 2267 | $162.08 | 299,502.0000 | 2,663,900,000 | 0.75% | 0.00% |
| Feb. 10, 2023 | Duato Joaquin | CEO and Chairman of the Board | M | Restricted Share Units | 5220 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Broadhurst Vanessa | EVP, Global Corp Affairs | M | Restricted Share Units | 1592 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | M | Common Stock | 2078 | $0.00 | 116,754.0055 | 2,663,900,000 | 1.81% | 0.00% |
| Feb. 10, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Common Stock | 1807 | $0.00 | 73,452.8735 | 2,663,900,000 | 2.52% | 0.00% |
| Feb. 10, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | F | Common Stock | 667 | $162.08 | 72,785.8735 | 2,663,900,000 | 0.91% | 0.00% |
| Feb. 10, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | M | Restricted Share Units | 1807 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Wolk Joseph J | Exec VP, CFO | M | Common Stock | 3449 | $0.00 | 41,249.2040 | 2,663,900,000 | 9.12% | 0.00% |
| Feb. 10, 2023 | Wolk Joseph J | Exec VP, CFO | F | Common Stock | 979 | $162.08 | 40,270.2040 | 2,663,900,000 | 2.37% | 0.00% |
| Feb. 10, 2023 | Wolk Joseph J | Exec VP, CFO | M | Restricted Share Units | 3449 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | M | Common Stock | 3570 | $0.00 | 130,026.0010 | 2,663,900,000 | 2.82% | 0.00% |
| Feb. 10, 2023 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | F | Common Stock | 1289 | $162.08 | 128,737.0010 | 2,663,900,000 | 0.99% | 0.00% |
| Feb. 10, 2023 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | M | Restricted Share Units | 3570 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | McEvoy Ashley | EVP, WW Chair, MedTech | M | Common Stock | 2999 | $0.00 | 47,834.9545 | 2,663,900,000 | 6.69% | 0.00% |
| Feb. 10, 2023 | McEvoy Ashley | EVP, WW Chair, MedTech | F | Common Stock | 823 | $162.08 | 47,011.9545 | 2,663,900,000 | 1.72% | 0.00% |
| Feb. 10, 2023 | McEvoy Ashley | EVP, WW Chair, MedTech | M | Restricted Share Units | 2999 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Forminard Elizabeth | Executive VP, General Counsel | M | Common Stock | 1022 | $0.00 | 4,233.0000 | 2,663,900,000 | 31.83% | 0.00% |
| Feb. 10, 2023 | Hait William | See Remarks | M | Restricted Share Units | 3856 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Forminard Elizabeth | Executive VP, General Counsel | F | Common Stock | 380 | $162.08 | 3,853.0000 | 2,663,900,000 | 8.98% | 0.00% |
| Feb. 10, 2023 | Forminard Elizabeth | Executive VP, General Counsel | M | Restricted Share Units | 1022 | $0.00 | 0.0000 | 2,663,900,000 | 100.00% | 0.00% |
| Feb. 10, 2023 | Hait William | See Remarks | M | Common Stock | 3856 | $0.00 | 84,092.0000 | 2,663,900,000 | 4.81% | 0.00% |
| Jan. 17, 2023 | Gorsky Alex | Director | M | Common Stock | 547692 | $72.54 | 1,134,945.6710 | 2,663,900,000 | 93.26% | 0.02% |
| Jan. 17, 2023 | Gorsky Alex | Director | F | Common Stock | 366610 | $173.43 | 768,335.6710 | 2,663,900,000 | 32.30% | 0.01% |
| Jan. 17, 2023 | Gorsky Alex | Director | M | Employee Stock Options (Right to Buy) | 547692 | $72.54 | 0.0000 | 2,663,900,000 | 100.00% | 0.02% |
| Jan. 17, 2023 | Duato Joaquin | CEO and Chairman of the Board | M | Common Stock | 148538 | $72.54 | 395,336.0000 | 2,663,900,000 | 60.19% | 0.01% |
| Jan. 17, 2023 | Duato Joaquin | CEO and Chairman of the Board | F | Common Stock | 98795 | $173.43 | 296,541.0000 | 2,663,900,000 | 24.99% | 0.00% |
| Jan. 17, 2023 | Duato Joaquin | CEO and Chairman of the Board | M | Employee Stock Options (Right to Buy) | 148538 | $72.54 | 0.0000 | 2,663,900,000 | 100.00% | 0.01% |